Abuja – Nigeria has introduced lenacapavir, a new long‑acting injectable medicine for HIV prevention, marking a significant step in the country’s efforts to reduce new infections and advance national HIV goals. The Federal Ministry of Health and Social Welfare launched the intervention with support from World Health Organization (WHO), the Global Fund, United States President’s Emergency Plan for AIDS Relief (PEPFAR) and partners.
The rollout aligns with national priorities set out in the Health Sector Renewal Investment Initiative and the National HIV/AIDS Strategic Framework 2023–2027, which call for expanded access to effective prevention tools, reduced inequalities and stronger integration of HIV services within primary health care.
A timely option for people who need more choices
Nigeria has approximately an estimated 1.9 million people living with HIV. Young women and key populations continue to carry a significant share of the burden. Many people who could benefit from pre‑exposure prophylaxis (PrEP) report challenges with daily oral medication, including adherence, stigma and access.
Lenacapavir provides an alternative. It is taken as a single injection every six months. Findings from the Purpose 1 and Purpose 2 studies, published in the New England Journal of Medicine, showed high levels of protection for people at substantial risk of HIV.
This offers a new option for those who prefer less frequent dosing or face barriers to daily pills.
During the national launch, the Coordinating Minister of Health and Social Welfare, Professor Muhammad Ali Pate, said the intervention reflects Nigeria’s commitment to applying innovation to reduce new HIV infection